Last A$0.50 AUD
Change Today 0.00 / 0.00%
Volume 0.0
As of 12:16 AM 04/30/14 All times are local (Market data is delayed by at least 15 minutes).

healthlinx ltd (HTX) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for HEALTHLINX LTD (HTX)

Related News

No related news articles were found.

healthlinx ltd (HTX) Related Businessweek News

No Related Businessweek News Found

healthlinx ltd (HTX) Details

HealthLinx Limited, a biomarker and diagnostic company, focuses on the development of novel blood based diagnostics for targeted diseases that have un-met market need. The company operates in three segments: Cryptomics, Diagnostics, and Peptide Research. It develops OvPlex, an ovarian cancer diagnostic targeting early detection of ovarian cancer in symptomatic women. HealthLinx Limited distributes its OvPlex primarily in Australia, Singapore, Malaysia, and the United Kingdom. The company is based in Melbourne, Australia.

healthlinx ltd (HTX) Top Compensated Officers

Secretary and Director
Total Annual Compensation: --
General Manager of Australian Operations
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

healthlinx ltd (HTX) Key Developments

Healthlinx Limited Reports Audited Consolidated Earnings Results for the Year Ended June 30, 2014

HealthLinx Limited reported audited consolidated earnings results for the year ended June 30, 2014. For the period, the company reported revenue of AUD 7,192 against AUD 34,721 for the same period last year. Total revenue and other income was AUD 64,734 against AUD 50,493 for the same period last year. Loss before income tax was AUD 363,677 against AUD 4,365,297 for the same period last year. Net loss was AUD 270,682 or 0.0219 cents per basic and diluted share against AUD 3,952,613 or 0.006 cents per basic and diluted share for the same period last year. Net cash used in operating activities was AUD 353,525 against AUD 661,153 for the same period last year.

HealthLinx Limited Auditor Raises 'Going Concern' Doubt

HealthLinx Limited filed its Annual on Nov 19, 2014 for the period ending Jun 30, 2014. In this report its auditor, Grant Thornton, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

HealthLinx Limited Appoints Timothy Chapman as Director

The board of HealthLinx Limited announced that it has appointed Mr. Timothy Chapman as a director. Mr. Chapman is currently a principal of Halcyon Corporate Pty Ltd. and has over 14 years' experience in the financial services industry. Mr. Chapman has advised and worked on numerous capital raisings for public and private companies in the form of initial public offerings, reverse take-overs, private placements and right issues, as well as many merger and acquisition transactions.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HTX:AU A$0.50 AUD 0.00

HTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HTX.
View Industry Companies

Industry Analysis


Industry Average

Valuation HTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,667.8x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,643.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HEALTHLINX LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at